HCW Biologics (HCWB) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HCW Biologics is the larger company by market cap ($3.4 million vs $453,907), about 7.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCWB | SXTC |
|---|---|---|
| Share price | $1.53 | $0.3435 |
| Market cap | $3.42M | $453.91K |
| 1-day change | -1.92% | -87.86% |
| EPS (TTM) | $-19.84 | $-730.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.57 | $83,760.00 |
| 52-week low | $1.50 | $0.31 |
| Distance from 52-week high | -94.45% | -100.00% |
| Analyst consensus | buy | — |
| Avg. price target upside | +3037.25% | — |
| Average volume | 376.23K | 4.71M |
| Shares outstanding | 2.24M | 1.32M |
| Employees | 35 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HCW Biologics is about 7.5 times larger than China SXT Pharmaceuticals by market value ($3.42M vs $453.91K).
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
HCWB vs SXTC FAQ
Which is bigger, HCW Biologics or China SXT Pharmaceuticals?
HCW Biologics (HCWB) is larger, with a market capitalization of $3.42M compared with $453.91K for China SXT Pharmaceuticals (SXTC).
Are HCW Biologics and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.